Biogen (BIIB)
(Real Time Quote from BATS)
$224.13 USD
+2.63 (1.19%)
Updated May 13, 2024 12:52 PM ET
3-Hold of 5 3
B Value B Growth B Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BIIB 224.13 +2.63(1.19%)
Will BIIB be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for BIIB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BIIB
Ionis (IONS) Q1 Loss Narrower Than Expected, Sales Miss
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
BIIB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
Denali (DNLI) Q1 Earnings Miss, Pipeline Progress in Focus
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
Other News for BIIB
Jim Cramer Likes Micron And Its CEO, Recommends Buying This Big Bank
3 S&P 500 Stocks to Rival Nvidia’s 2023 Performance in the Second Half of 2024
The 3 Most Undervalued Pharma Stocks to Buy in May 2024
Eli Lilly Alzheimer’s therapy set for June FDA AdCom meeting
U.S. Wide-Moat Stocks On Sale - The May 2024 Heat Map